Truist analyst Srikripa Devarakonda raised the firm’s price target on Scholar Rock (SRRK) to $55 from $44 and keeps a Buy rating on the shares. The firm cites the company’s earnings call where the management remained positive on the developments at Catalent and Scholar Rock’s ability to resubmit apitegromab’s BLA in 2026, potentially supporting FDA approval and launch in 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock price target raised to $58 from $51 at Piper Sandler
- Scholar Rock: Positive Regulatory Trajectory and Commercial Readiness for Apitegromab Support Buy Rating and Multi‑Billion‑Dollar SMA Potential
- Scholar Rock price target raised to $70 from $50 at BMO Capital
- Scholar Rock price target raised to $58 from $55 at Citi
- Scholar Rock price target raised to $53 from $52 at Barclays